{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:46:28Z","timestamp":1791193588745,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s00228-006-0111-5","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T17:57:28Z","timestamp":1146074248000},"page":"423-429","source":"Crossref","is-referenced-by-count":146,"title":["CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis"],"prefix":"10.1007","volume":"62","author":[{"given":"Nicolas","family":"Vuilleumier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel F.","family":"Rossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Degoumois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Mermillod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Nicod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Desmeules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Hochstrasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"111_CR1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","volume":"282","author":"C Dye","year":"1999","unstructured":"Dye C (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677\u2013686","journal-title":"JAMA"},{"key":"111_CR2","first-page":"394","volume":"16","author":"F Durant","year":"1996","unstructured":"Durant F, Jebrak G, Pessayre D, Fournier M, Bernau J (1996) Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 16:394\u2013405","journal-title":"Drug Saf"},{"key":"111_CR3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00003246-200002000-00047","volume":"28","author":"I Martinjak-Dvorsek","year":"2000","unstructured":"Martinjak-Dvorsek I, Gorjup V, Horvat M, Noc M (2000) Acute isoniazid neurotoxicity during preventive therapy. Crit Care Med 28:567\u2013568","journal-title":"Crit Care Med"},{"key":"111_CR4","first-page":"57","volume":"82","author":"RC Watkins","year":"1990","unstructured":"Watkins RC, Hambrick EL, Benjamin G, Chavda SN (1990) Isoniazid toxicity presenting as seizures and metabolic acidosis. J Natl Med Assoc 82:57\u201364","journal-title":"J Natl Med Assoc"},{"key":"111_CR5","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","volume":"9","author":"T Schaberg","year":"1996","unstructured":"Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9:2026\u20132030","journal-title":"Eur Respir J"},{"key":"111_CR6","unstructured":"Morant J, Ruppaner H (2003) Compendium Suisse des M\u00e9dicaments, 24th edn. Documed, Geneva"},{"key":"111_CR7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472\u20131477","journal-title":"Am J Respir Crit Care Med"},{"key":"111_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","volume":"99","author":"MA Steele","year":"1991","unstructured":"Steele MA, Burk RF, DesPrez RM (1991) Toxic hepatitis with isoniazid and rifampin a meta-analysis. Chest 99:465\u2013471","journal-title":"Chest"},{"key":"111_CR9","first-page":"1072","volume":"133","author":"GR Saram","year":"1986","unstructured":"Saram GR, Imanuel C, Kailasam S, Narayana ASL, Venkatesan P (1986) Rifampin \u2013induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regiments containing isoniazid and rifampin. Am Rev Dis 133:1072\u20131075","journal-title":"Am Rev Dis"},{"key":"111_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt197518170","volume":"18","author":"JR Mitchell","year":"1975","unstructured":"Mitchell JR, Thorgeisson UP, Black M et al (1975) Increased incidence of isoniazid hepatitis in rapid acetylators : possible relation to hydralazine metabolites. Clin Pharmacol Ther 18:70\u201379","journal-title":"Clin Pharmacol Ther"},{"key":"111_CR11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0016-5085(19)32568-5","volume":"69","author":"M Black","year":"1975","unstructured":"Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Elper GR (1975) Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69:289\u2013302","journal-title":"Gastroenterology"},{"key":"111_CR12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","volume":"84","author":"JR Mitchell","year":"1976","unstructured":"Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeisson UP, Timbrell JA, Snodgrass WR, Nelson SD (1976) Isoniazid Liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 84:181\u2013192","journal-title":"Ann Intern Med"},{"key":"111_CR13","doi-asserted-by":"crossref","unstructured":"Spielberg SP (1996) N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphism drug metabolism. J Pharmacokinet Biopharm 509\u201319","DOI":"10.1007\/BF02353477"},{"key":"111_CR14","first-page":"43","volume":"39","author":"J Singh","year":"1995","unstructured":"Singh J, Garg PK, Thakur VS, Tandon RK (1995) Anti-tubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 39:43\u201346","journal-title":"Indian J Physiol Pharmacol"},{"key":"111_CR15","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1016\/S0021-9258(18)88984-0","volume":"260","author":"DE Ryan","year":"1985","unstructured":"Ryan DE, Ramanathan L, Iilda S, Thomas PE, Hainu M, Shively JE, Lieber CS et al (1985) Characterisation of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem 260:6385\u20136393","journal-title":"J Biol Chem"},{"key":"111_CR16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajmg.1320570413","volume":"57","author":"I Cascorbi","year":"1995","unstructured":"Cascorbi I, Drakoulis N, Brockm\u00f6ller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyl transferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individual: correlation with phenotypic activity. Am J Hum Gen 57:581\u2013592","journal-title":"Am J Hum Gen"},{"key":"111_CR17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","volume":"155","author":"PD Parkin","year":"1997","unstructured":"Parkin PD, VandenPlas S, Botha FJH (1997) Trimodality of isoniazid elimination. Phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155:1717\u20131722","journal-title":"Am J Respir Crit Care Med"},{"key":"111_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/jmg.34.9.758","volume":"34","author":"CAD Smith","year":"1997","unstructured":"Smith CAD, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A (1997) A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 34:758\u2013760","journal-title":"J Med Genet"},{"key":"111_CR19","first-page":"256","volume":"4","author":"M Ohno","year":"2000","unstructured":"Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, et al (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256\u2013261","journal-title":"Int J Tuberc Lung Dis"},{"key":"111_CR20","first-page":"58","volume":"129","author":"P Gurumutry","year":"1984","unstructured":"Gurumutry P, Krishnamurthy MS, Nasareth O (1984) Parthasarthy R, Samara GR, Somasundaram PR, Tripathy SP et al (1984) Lack of relationship between hepatotoxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 129:58\u201361","journal-title":"Am Rev Respir Dis"},{"key":"111_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004836-198109000-00012","volume":"3","author":"DS Dickinson","year":"1981","unstructured":"Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM (1981) Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol 3:271\u2013279","journal-title":"J Clin Gastroenterol"},{"key":"111_CR22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1152\/physrev.1997.77.2.517","volume":"77","author":"CS Lieber","year":"1997","unstructured":"Lieber CS (1997) Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 77:517\u2013544","journal-title":"Physiol Rev"},{"key":"111_CR23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2710.2000.00282.x","volume":"25","author":"E Tanaka","year":"2000","unstructured":"Tanaka E, Terarda M ,Misawa S (2000) Cytochrome P4502E1.Its clinical and toxicological role. J Clin Pharm Ther 25:165\u2013175","journal-title":"J Clin Pharm Ther"},{"key":"111_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0378-4274(00)00287-3","volume":"124","author":"D Lucas","year":"2001","unstructured":"Lucas D, Ferrara R, Gonzales E, Albores A, Manno M, Berthou F (2001) Cytochrome CYP2E1 phenotyping and genotyping in the evaluation of health risks from exposure to polluted environments. Toxicol Lett 124:71\u201381","journal-title":"Toxicol Lett"},{"key":"111_CR25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/mp.53.2.88","volume":"53","author":"NACS Wong","year":"2000","unstructured":"Wong NACS, Rae F, Simpson KJ, Murray GD, Harrison DJ (2000) Genetic polymorphism of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta analysis. J Clin Pathol Mol Pathol 53:88\u201393","journal-title":"J Clin Pathol Mol Pathol"},{"key":"111_CR26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00420-002-0334-4","volume":"75","author":"V Haufroid","year":"2002","unstructured":"Haufroid V, Buchet JP, Gardinal S, Lison D (2002) Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int Arch Occup Environ Health 75:453\u2013458","journal-title":"IntArch Occup Environ Health"},{"key":"111_CR27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","volume":"37","author":"YS Huang","year":"2003","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY et al (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculous drug-induced hepatitis. Hepatology 37:924\u2013930","journal-title":"Hepatology"},{"issue":"4","key":"111_CR28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","volume":"35","author":"YS Huang","year":"2002","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY et al (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4):883\u2013889","journal-title":"Hepatology"},{"key":"111_CR29","first-page":"1","volume":"49","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recommendation Rep 49:1\u201351","journal-title":"MMWR Recommendation Rep"},{"key":"111_CR30","first-page":"991","volume":"117","author":"DE Kopanoff","year":"1978","unstructured":"Kopanoff DE, Snider DE, Caras GJ (1978) Isoniazid related hepatitis : A US public health service cooperative surveillance study. Am Rev Resp Dis 117:991\u20131001","journal-title":"Am Rev Resp Dis"},{"key":"111_CR31","first-page":"1978","volume":"90","author":"LA Ozick","year":"1995","unstructured":"Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, Donelson SS, Felton CP (1995) Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 90:1978\u20131980","journal-title":"Am J Gastroenterol"},{"key":"111_CR32","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0168-8278(00)80127-0","volume":"33","author":"P Guruprasad","year":"2000","unstructured":"Guruprasad P. Aithal GP, Rawlins MD, Day CP (2000) Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 33:949\u2013952","journal-title":"J Hepatol"},{"key":"111_CR33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2307\/2532296","volume":"48","author":"SW Guo","year":"1992","unstructured":"Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48:361\u2013372","journal-title":"Biometrics"},{"key":"111_CR34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00008571-199712000-00009","volume":"7","author":"HG Xie","year":"1997","unstructured":"Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, Yan XD et al (1997) Metaanalysis of phenotype and genotype of NAT2 deficiency in Chinese population. Pharmacogenetics 7:503\u2013514","journal-title":"Pharmacogenetics"},{"key":"111_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00008571-199902000-00016","volume":"9","author":"I Cascorbi","year":"1999","unstructured":"Cascorbi I, Roots I (1999) Pitfalls in N-acetyltransferase-2 genotyping. Pharmcogenetics 9:123\u2013127","journal-title":"Pharmcogenetics"},{"key":"111_CR36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00008571-199708000-00008","volume":"7","author":"AS Aynacioglu","year":"1997","unstructured":"Aynacioglu AS, Cascorbi I, Mrozikiewics PM, Roots I (1997) Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. Pharmacogenetics 7:327\u2013331","journal-title":"Pharmacogenetics"},{"key":"111_CR37","unstructured":"Mandell GL, Petri WA (1996) Antimicrobial agents. In: Goodman G (eds) The pharmacological basis of therapeutics 9th edn. Donnelley and Sons, Chicago, Ill., pp 1155\u20131174"},{"issue":"4","key":"111_CR38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1067\/mcp.2000.110561","volume":"68","author":"RA Branch","year":"2000","unstructured":"Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M (2000) In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 68:401\u2013411","journal-title":"Clin Pharmacol Ther"},{"key":"111_CR39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.1993.125","volume":"54","author":"R Zand","year":"1993","unstructured":"Zand R, Nelson SD, Slaterry JT, Thummel KE, Kalhorn TF, Adams SP, Wright JM (1993) Inhibition and induction of cytochrome P4502E1-catalysed oxidation by isoniazid in humans. Clin Pharmacol Ther 54:142\u2013149","journal-title":"Clin Pharmacol Ther"},{"key":"111_CR40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1746.1997.tb00353.x","volume":"12","author":"SJ Hwang","year":"1997","unstructured":"Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CJ, Lin TP, Lee SD (1997) A prospective clinical study of isoniazid-rifampicin-pyrazinamid-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 12:87\u201391","journal-title":"J Gastroenterol Hepatol"},{"key":"111_CR41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","volume":"31","author":"WM Wong","year":"2000","unstructured":"Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM et al (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31:201\u2013206","journal-title":"Hepatology"},{"key":"111_CR42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/hep.1840060223","volume":"6","author":"T Yamamoto","year":"1986","unstructured":"Yamamoto T, Suou T, Hirayama C (1986) Elevated serum amino-transferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6:295\u2013298","journal-title":"Hepatology"},{"key":"111_CR43","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","volume":"149","author":"American Thoracic Society","year":"1994","unstructured":"American Thoracic Society (1994) Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Resp Crit Care Med 149:1359\u20131374","journal-title":"Am J Resp Crit Care Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0111-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0111-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0111-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T03:52:02Z","timestamp":1627271522000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0111-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0111-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}